Opendata, web and dolomites

MIAMi SIGNED

Refactoring monoterpenoid indole alkaloid production in microbial cell factories

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MIAMi project word cloud

Explore the words cloud of the MIAMi project. It provides you a very rough idea of what is the project "MIAMi" about.

factories    tabersonine    plant    rauwolscine    metabolites    learning    genome    monoterpenoid    industry    benefits    therapeutics    prototype    showcase    yeast    treat    alkaloids    inter    localisation    standardisation    sectorial    treatment    plants    biological    biosynthetic    cad    alstonine    biotech    strictosidine    producing    automated    benefit    parts    discovery    excellent    data    cell    psychosis    market    omics    standardised    sub    secondary    remarkable    trackable    elucidated    supervised    mia    inventory    expression    pharmaceutically    mias    sampled    repository    bio    millennia    potent    therapies    valuable    medicines    refactoring    represented    sops    drug    protein    bioactivity    algorithms    indole    environmental    precursor    environment    illnesses    diversity    leads    founded    microbial    designs    risks    health    structural    miami    commercially    interactions    gt    public    cellular    compartmentalised    dna    human    interdisciplinary    nature    bioengineering    chains    engineering    sustainable    cancer    characterisation    gene    chemicals    genetically   

Project "MIAMi" data sheet

The following table provides information about the project.

Coordinator
DANMARKS TEKNISKE UNIVERSITET 

Organization address
address: ANKER ENGELUNDSVEJ 1 BYGNING 101 A
city: KGS LYNGBY
postcode: 2800
website: www.dtu.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 6˙648˙301 €
 EC max contribution 6˙648˙301 € (100%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
 Code Call H2020-NMBP-BIO-2018-two-stage
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DANMARKS TEKNISKE UNIVERSITET DK (KGS LYNGBY) coordinator 1˙438˙313.00
2    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) participant 1˙511˙371.00
3    UNIVERSITE DE TOURS FR (TOURS) participant 1˙165˙125.00
4    FUTURE GENOMICS TECHNOLOGIES BV NL (LEIDEN) participant 853˙750.00
5    EXPLORA SRL IT (ROMA) participant 719˙250.00
6    AXYNTIS FR (PARIS) participant 619˙375.00
7    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 341˙116.00
8    JOHN INNES CENTRE UK (NORWICH) participant 0.00

Map

 Project objective

Plants produce some of the most potent human therapeutics and have been used for millennia to treat illnesses. The monoterpenoid indole alkaloids (MIAs) are plant secondary metabolites that show a remarkable structural diversity and pharmaceutically valuable biological activities with more than 2,000 MIAs derived from the common precursor strictosidine. However, because most MIA chemicals do not have their biosynthetic pathways elucidated and MIA-producing plants are not genetically trackable, MIAs are under-represented in recently introduced medicines. In the consortium for Refactoring of Monoterpenoid Indole Alkaloids in Microbial Cell Factories (MIAMi) our main objective is to develop sustainable microbial production of new human therapies for the benefit of the European biotech industry, human health, and the environment. To do so, MIAMi will i) develop a new approach for MIA biosynthetic pathway discovery in plants founded on supervised learning algorithms based on omics data sampled from > 20 MIA producing plants, ii) contribute to standardisation of bioengineering by development of SOPs for characterisation of > 100 DNA elements for control of gene expression, protein interactions, and sub-cellular localisation, iii) build a public parts repository and Bio-CAD for forward engineering of compartmentalised biosynthetic pathway designs in yeast, and iv) apply automated genome engineering to prototype > 1,000 new-to-nature MIA biosynthetic pathway designs in order to identify robust designs for scale-up microbial MIA production processes, and evaluate the environmental benefits and risks compared to existing value chains. The excellent, interdisciplinary and inter-sectorial consortium will showcase the use of the new approaches and standardised data inventory to produce both commercially available and new-to-market MIAs rauwolscine, tabersonine and alstonine in yeast, and finally test their bioactivity as new cancer and psychosis treatment drug leads.

 Publications

year authors and title journal last update
List of publications.
2020 Thomas Dugé de Bernonville, Nicolas Papon, Marc Clastre, Sarah E. O’Connor, Vincent Courdavault
Identifying Missing Biosynthesis Enzymes of Plant Natural Products
published pages: , ISSN: 0165-6147, DOI: 10.1016/j.tips.2019.12.006
Trends in Pharmacological Sciences 2020-02-20

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIAMI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIAMI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.)

SHIKIFACTORY100 (2019)

Modular cell factories for the production of 100 compounds from the shikimate pathway

Read More  

BioRoboost (2018)

Fostering Synthetic Biology standardisation through international collaboration

Read More  

SynBio4Flav (2019)

Synthetic microbial consortia-based platform for flavonoids production using synthetic biology

Read More